Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Erastin: Precision Ferroptosis Inducer for Advanced Cance...

    2026-02-13

    Unlocking the Power of Erastin: A Precision Ferroptosis Inducer in Cancer Biology Research

    Principle Overview: Erastin and the Ferroptosis Revolution

    Ferroptosis, a distinct form of iron-dependent, caspase-independent cell death, has emerged as a transformative paradigm in cancer biology research. Unlike apoptosis or necrosis, ferroptosis is characterized by lethal accumulation of reactive oxygen species (ROS) and lipid peroxides, particularly in tumor cells with aberrant redox regulation. Erastin (CAS 571203-78-6), supplied by APExBIO, stands at the forefront of this revolution as a selective ferroptosis inducer and potent inhibitor of the cystine/glutamate antiporter system Xc⁻. By targeting the voltage-dependent anion channel (VDAC) and system Xc⁻, Erastin disrupts cellular antioxidant defenses, leading to iron-dependent oxidative damage and robust cell death in cancer models, especially those harboring KRAS or BRAF mutations.

    The clinical significance of this mechanism is underscored by integrative studies, such as Ren et al. (2022), which highlighted the role of ferroptosis regulation in hepatocellular carcinoma (HCC) and identified key transcriptional targets like TEAD2 as prognostic markers. Their findings illuminate how ferroptosis inducers like Erastin can be leveraged to interrogate oncogenic signaling and resistance pathways, offering new therapeutic avenues beyond conventional apoptosis-based strategies.

    Step-by-Step Workflow: Optimized Protocols for Ferroptosis Research

    1. Cell Model Selection and Preparation

    • Target Cells: Select tumor cell lines with known RAS (HRAS, KRAS) or BRAF mutations. Common models include engineered human tumor cells and HT-1080 fibrosarcoma cells.
    • Controls: Include wild-type or non-mutant lines for specificity assessment. Consider knockdowns of ferroptosis-related genes (e.g., GPX4, SLC7A11) for mechanistic validation.

    2. Compound Handling and Solution Preparation

    • Solubility: Erastin is insoluble in water and ethanol. Dissolve in DMSO at ≥10.92 mg/mL with gentle warming (avoid excessive heat to maintain stability).
    • Storage: Store solid Erastin at -20°C. Prepare solutions freshly before each experiment, as Erastin is not stable in solution for long-term storage.

    3. Treatment Setup

    • Concentration: Standard conditions use 10 μM Erastin for 24 hours. For dose-response studies, test a range (1–20 μM) to determine the IC50 in your system.
    • Controls: Include vehicle (DMSO) and, where appropriate, ferroptosis inhibitors (e.g., ferrostatin-1) to confirm pathway specificity.

    4. Readouts and Assays

    • Cell Viability: MTT, CellTiter-Glo, or trypan blue exclusion assays to assess cytotoxicity.
    • Oxidative Stress Assays: Measure ROS using DCFDA or lipid peroxidation (BODIPY 581/591 C11).
    • Iron Dependency: Use iron chelators (e.g., deferoxamine) as rescue controls to confirm iron-dependent non-apoptotic cell death.

    5. Data Analysis

    • Normalize results to vehicle controls and perform statistical tests (ANOVA, t-test) for significance.
    • Correlate ferroptosis sensitivity with genetic or transcriptomic profiles (e.g., RAS status, TEAD2 expression).

    Advanced Applications and Comparative Advantages

    Erastin’s specificity for tumor cells with KRAS or BRAF mutations makes it a unique tool in dissecting oncogenic signaling pathways such as the RAS-RAF-MEK cascade. This aligns with recent findings from Ren et al. (2022), who demonstrated that modulation of TEAD2—a downstream effector in the Hippo pathway—can sensitize HCC cells to ferroptosis. By integrating Erastin into experimental workflows, researchers can directly interrogate caspase-independent cell death and uncover novel mechanisms of cancer therapy targeting ferroptosis.

    Comparative Article Integration:

    Notably, Erastin’s ability to induce rapid, iron-dependent cell death (often within 24 hours at 10 μM) surpasses many traditional apoptosis inducers, especially in RAS/BRAF-mutant backgrounds where resistance to caspase-dependent therapies is common. Quantitative studies have shown up to 70–90% reduction in viability in sensitive tumor models, underscoring its potency and translational promise [source].

    Troubleshooting and Optimization Tips

    • Compound Precipitation: Ensure Erastin is fully dissolved in DMSO before dilution; vortex and gently warm if needed. Avoid freeze-thaw cycles of solutions.
    • Variable Sensitivity: If cells show weak response, verify mutation status (KRAS/BRAF), confirm redox-related gene expression, and rule out culture artifacts (e.g., over-confluency, serum antioxidants).
    • Assay Interference: DMSO concentrations above 0.2% can affect cell viability. Match vehicle controls precisely.
    • Iron Chelation Artifacts: Overuse of iron chelators in rescue experiments can mask ferroptosis specificity. Titrate carefully and include appropriate controls.
    • Batch Variation: Use validated Erastin from APExBIO to minimize variability. Record lot numbers and solution preparation details for reproducibility.

    Additional troubleshooting strategies and protocol enhancements are discussed in depth in "Erastin: Precision Ferroptosis Inducer for Cancer Biology", which serves as an extension for researchers optimizing oxidative stress assays and system Xc⁻ inhibition workflows.

    Future Outlook: Ferroptosis Research and Translational Frontiers

    The role of ferroptosis in cancer therapy targeting ferroptosis is rapidly expanding, with Erastin at the core of preclinical models aimed at overcoming apoptosis resistance. Current trends emphasize integrating ferroptosis inducers with immunotherapies and exploiting vulnerabilities in the tumor microenvironment—as highlighted by TEAD family regulation in HCC (Ren et al., 2022).

    Emerging directions include:

    • High-throughput screening of novel ferroptosis modulators using Erastin as a benchmark.
    • Patient-derived organoids and ex vivo tumor slices to model iron-dependent non-apoptotic cell death in clinically relevant settings.
    • Systems biology approaches to map ferroptosis signaling networks and identify synthetic lethal interactions with RAS-RAF-MEK pathway inhibitors.

    As the field matures, validated tools like Erastin from APExBIO will remain indispensable for rigorous, reproducible ferroptosis research, enabling new discoveries in cancer biology, oxidative stress, and beyond.